Heilongjiang Tianlong Pharmaceutical, Inc. ("Tianlong"), a wholly-owned subsidiary of China Sky One Medical, Inc., recently completed research and development for eight different types of injections, obtaining production approval for three injections, including the propyl gallate injection. The production process for the propyl gallate injection is complex, and only seven other manufacturers are currently able to produce it.
"We are very excited about the development of a propyl gallate injection,"
said Mr.
About China Sky One Medical, Inc.
China Sky One Medical, Inc., a
Safe Harbor Statement
Certain of the statements made in the press release constitute forward-
looking statements within the meaning of the Private Securities Litigation
Reform Act of 1995. These statements can be identified by the use of forward-
looking terminology such as "believe," "expect," "may," "will," "should,"
"project," "plan," "seek," "intend," or "anticipate" or the negative thereof
or comparable terminology. Such statements typically involve risks and
uncertainties and may include financial projections or information regarding
our future plans, objectives or performance. Actual results could differ
materially from the expectations reflected in such forward-looking statements
as a result of a variety of factors, including the risks associated with the
effect of changing economic conditions in
For more information, please contact:
Company Contact:
China Sky One Medical, Inc.
Ms. Yanwei Zhang, Board Secretary
Tel: +86-451-53994064
Email: cntiandiren@yahoo.com.cn
Investor Relations Contact:
CCG Elite Investor Relations
Mr. Crocker Coulson, President
Tel: +1-646-213-1915
Email: crocker.coulson@ccgir.com
Mr. Richard Micchelli, Financial Writer
Tel: +1-646-454-4516
Email: richard.micchelli@ccgir.com
Website: http://www.ccgelite.com
SOURCE China Sky One Medical, Inc.